Association of oral outpatient antiviral medications for COVID-19 with the risk of post-acute sequelae of COVID-19 at 28 and 90&#160;days in a cohort of individuals with systemic autoimmune rheumatic diseases.

Paxlovid (nirmatrelvir/ritonavir) - Pfizer

Lagevrio (molnupiravir) - Ridgeback Biotherap, Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/42461564

Alene A Saavedra; Grace Qian; Jeffrey A Sparks; Jiaqi Wang; Kevin T Mueller; Lauren A O'Keeffe; Liya S Getachew; Madison Negron; Naomi J Patel; Natalie A Davis; Xiaosong Wang

Jul 17, 2026